Announcements & Media Coverage

Presentation at H.C. Wainwright Global Investment Conference - 12:46 1/01/2022
Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)   Presentation at H.C. Wainwright Global Investment Conference   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright 24th Annual Global Investment Conference to be held on September 12-14, 2022,...
Read
Total Market Solutions interview with Dr Vladislav Sandler – Interesting Times Ahead for Hemogenyx Pharmaceuticals - 13:56 22/22/2022
Read

About Us

Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases

UK Headquarters

6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdom

Research Facility

1361 Amsterdam Ave., Suite 320, New York, NY 10027, USA

Contact Us

© Hemogenyx Pharmaceuticals plc 2017--2022. All rights reserved. Hemogenyx Pharmaceuticals plc is registered in England and Wales as company number 08401609 at 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdom. LEI 2138008L93GYU5GN6179.